Point-of-Sale Rebates

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Vivamus magna. Cras in mi at felis aliquet congue. Ut a est eget ligula molestie gravida. Curabitur massa. Donec eleifend, libero at sagittis mollis, tellus est malesuada tellus, at luctus turpis elit sit amet quam. Vivamus pretium ornare est.

Filter by Document Type

2025 VA SB 1078 Testimony

View Document >

VT H 233 Amendment Testimony: Spread, POS Rebates, Accumulator, Right of Action (2024)

View Document >

VA HB 1041 Comment Letter: Delinking, POS Rebates, Fiduciary (2024)

View Document >

VT H 233 Veto Reqeuest Comment Letter: Spread, POS, Coupons, Copay Accumulator (2024)

View Document >

Abbreviated Analysis of California Assembly Bill 933 Prescription Drug Cost Sharing and Point of Sale Rebates

View Document >

GAO Medicare Part D Rebates Report

View Document >

Impact of Medicare Part D Drug Manufacturer Rebates at the Point-of-Sale (2020)

View Document >

Mandated POS Rebates Legislation Would Increase Costs for the States (2-pager, 2024)

View Document >

Oppose Mandatory Point-of-Sale Prescription Drug Rebates: A Windfall for Drug Manufacturers (Talking Points, 2023)

View Document >

What Are Point-of-Sale (POS) Rebates? (Explainer, 2023)

View Document >

AR HB 1481 Veto Letter (2023)

Veto request letter for AR HB 1481, a point-of-sale rebate bill.

View Document >

With Point of Sale Rebates, Everyone Pays Except Manufacturers (2021)

One Pager highlight how drug companies benefit from point-of-sale rebate mandates.

View Document >

Pharmaceutical Care
Management Association

325 7th Street, NW
Washington, DC 20004
Main: 202.756.5700

©2024 PCMA. All Rights Reserved.